GATA-3 as a Potential Therapeutic Target for Insulin Resistance and Type 2 Diabetes Mellitus

被引：13

作者：

Al-Jaber, Hend ^{[1
]}

Al-Mansoori, Layla ^{[1
]}

Elrayess, Mohamed A. ^{[1
]}

机构：

[1] Qatar Univ, Biomed Res Ctr, Doha, Qatar

来源：

CURRENT DIABETES REVIEWS | 2021年 / 17卷 / 02期

关键词：

GATA-3; therapeutic target; insulin resistance; adipogenesis; inflammation; type; 2; diabetes; TUMOR-NECROSIS-FACTOR; ADIPOSE-TISSUE INFLAMMATION; HUMAN SUBCUTANEOUS ADIPOGENESIS; REGULATORY T-CELLS; TRANSCRIPTION FACTORS; METABOLICALLY HEALTHY; FACTOR-ALPHA; INHIBITS ADIPOGENESIS; IMPAIRED ADIPOGENESIS; LINKING OBESITY;

D O I：

10.2174/1573399816666200705210417

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Impaired adipogenesis plays an important role in the development of obesity-associated insulin resistance and type 2 diabetes as it leads to ectopic fat deposition. The anti-adipogenic transcription factor GATA-3 was identified as one of the potential molecular targets responsible for the impairment of adipogenesis. The expression of GATA-3 is higher in insulinresistant obese individuals compared to BMI-matched insulin-sensitive counterparts. Adipose tissue inflammation is a crucial mediator of this process. Hyperglycemia mediates the activation of the immune system, partially through upregulation of GATA-3, causing exacerbation of the inflammatory state associated with obesity. This review discusses the evidence supporting the inhibition of GATA-3 as a useful therapeutic strategy in obesity-associated insulin resistance and type 2 diabetes, through up-regulation adipogenesis and amelioration of the immune response.

引用

页码：169 / 179

页数：11

共 50 条

[1] The potential of therapeutic strategies targeting mitochondrial biogenesis for the treatment of insulin resistance and type 2 diabetes mellitus
Wenwen Ding
Xiaoxue Yang
Kaiyi Lai
Yu Jiang
Ying Liu
Archives of Pharmacal Research, 2024, 47 : 219 - 248
[2] The potential of therapeutic strategies targeting mitochondrial biogenesis for the treatment of insulin resistance and type 2 diabetes mellitus
Ding, Wenwen
Yang, Xiaoxue
Lai, Kaiyi
Jiang, Yu
Liu, Ying
ARCHIVES OF PHARMACAL RESEARCH, 2024, 47 (03) : 219 - 248
[3] Plin5: A potential therapeutic target for type 2 diabetes mellitus
Wei, Mengjuan
Wang, Yan
Zhang, Yufei
Qiao, Yun
DIABETOLOGY & METABOLIC SYNDROME, 2025, 17 (01):
[4] Insulin resistance: From predisposing factor to therapeutic target in type 2 diabetes
Henry, RR
CLINICAL THERAPEUTICS, 2003, 25 : B47 - B63
[5] Atherosclerosis in type 2 diabetes mellitus and insulin resistance: mechanistic links and therapeutic targets
Plutzky, J
Viberti, G
Haffner, S
JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2002, 16 (06) : 401 - 415
[6] Insulin resistance and type 2 diabetes mellitus: Is there a therapeutic role for IGF-1?
Moses, AC
IGF-I and IGF Binding Proteins: Basic Research and Clinical Management, 2005, 9 : 121 - 134
[7] Matriptase as a potential biomarker and therapeutic target in newly diagnosed type 2 diabetes mellitus
Ismail Demir
Ismail Yilmaz
Ersan Horoz
Bulent Calik
Oktay Bilgir
Irish Journal of Medical Science (1971 -), 2024, 193 : 223 - 230
[8] Matriptase as a potential biomarker and therapeutic target in newly diagnosed type 2 diabetes mellitus
Demir, Ismail
Yilmaz, Ismail
Horoz, Ersan
Calik, Bulent
Bilgir, Oktay
IRISH JOURNAL OF MEDICAL SCIENCE, 2024, 193 (01) : 223 - 230
[9] Insulin resistance syndrome and type 2 diabetes mellitus
Erkelens, DW
AMERICAN JOURNAL OF CARDIOLOGY, 2001, 88 (7B): : 38J - 42J
[10] Predicting type 2 diabetes mellitus and insulin resistance
Mohan, V.
INTERNATIONAL JOURNAL OF DIABETES IN DEVELOPING COUNTRIES, 2012, 32 (01) : 4 - 6

← 1 2 3 4 5 →